336 clinical trials
grid
list
download
Body (indexed field) | Identifiant (ID) | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
22670 | Progressive. At least 1 line of athracycline and/or taxane | Daphné t'Kint de Roodenbeke | Breast | AstraZeneca | VIOLETTE | Trial closed | A Phase II, Open Label, randomized, Multi-center Study to Assess the Safety and Efficacy of Agents Targeting DNA Damage Repair in Combination with Olaparib versus Olaparib Monotherapy in the Treatment of Metastatic Triple Negative Breast Cancer Patients Stratified by Alterations in Homologous Recombinant Repair (HRR-Related Genes (including BRCA 1/2) (VIOLETTE) | daphne.tkint@hubruxelles.be | 2 | 2 | |
22708 | *Must have received at least one NAAD(enzalutamide or abiraterone). *1 or 2 prior treatment with taxane *Progressive disease |
Carlos Artigas Guix | prostate | Endocyte | VISION | Trial closed | VISION: An international, prospective, open label, multicenter, randomized Phase 3 study of 177Lu-PSMA-617 in the treatment of patients with progressive PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) | carlos.artigas@hubruxelles.be | 3 | 3 | |
22694 | "3rd line metastatic " | Thierry Gil | Gastrointestinal stromal tumors (GIST) | Blueprint Medicines Corporation | Voyager | Trial closed | An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients with Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST) | thierry.gil@hubruxelles.be | 3 | 3 | |
22752 | Triple negative. Metastatic. 1st Line | Andrea Gombos | Breast | Roche | WO29522 | Trial closed | A Phase III, MULTICENTER, RANDOMIZED, placebo-controlled Study OF MPDL3280A (Anti-PD-L1 Antibody) IN COMBINATION WITH NAB-PACLITAXEL COMPARED with placebo with NAB-PACLITAXEL for PATIENTS WITH previously UNtreated metastatic TRIPLE-NEGATIVE BREAST CANCER | accueil.oncologie@hubruxelles.be | 3 | 3 | |
22755 | Absence of metastasis | Spyridon Sideris | Ureters - bladder - urethra | Roche | WO29636 | Trial closed | WO29636 A Phase III, Open-Label, Multicenter, Randomized Study Of Atezolizumab (Anti?Pd-L1 Antibody) Versus Observation As Adjuvant Therapy In Patients With High-Risk Muscle-Invasive Urothelial Carcinoma After Surgical Resection | spyridon.sideris@hubruxelles.be | 3 | 3 | |
22686 | HER2+. Early breast cancer | Evandro De Azambuja | Breast | Roche | WO40324 | Trial closed for recruitment | A phase III, randomized, multicenter, open-label, two-arm study to evaluate the pharmacokinetics, efficacy, and safety of subcutaneous administration of the fixed-dose combination of pertuzumab and trastuzumab in combination with chemotherapy in patients with HER2-positive early breast cancer | 3 | 3 | ||
29649 | Nieves Martinez Chanza | Colon | Exelixis | XL092-002 - Stellar 002 | Trial open for recruitment | A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors | nieves.martinez-chanza@hubruxelles.be | 1/1b | 1 | ||
22725 | RECIST 1.1 | Yassine Lalami | Thyroïd | Exelixis | XL184-311 | Trial closed | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Cabozantinib (XL184) in Subjects with Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed after Prior VEGFR-Targeted Therapy | yassine.lalami@hubruxelles.be | 3 | 3 | |
22834 | Intermediate or poor risk metastatic clear cell renal cell carcinoma in 1st line treatment. | Nieves Martinez Chanza | Multiple | Exelixis | XL184-313 | Trial closed for recruitment | A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk | nieves.martinez-chanza@hubruxelles.be | 3 | 3 | |
29752 | Christiane Jungels | Xenothera | XT 23-01 - FIPO23 | Trial open for recruitment | A Phase I/II Open Label, Multiple Dose, Dose Escalation and Expansion Trial to Investigate the Safety, Pharmacokinetic and Efficacy of the glyco-humanized polyclonal antibody XON7 in patients with Advanced Solid Tumors | christiane.jungels@hubruxelles.be | 1/2 | 1 | |||
22731 | Triple-negative breast cancer | Philippe Aftimos | Breast | Zenith Epigenetics Ltd. | ZEN003694-004 | Trial closed | A Phase 2 Study of ZEN003694 in Combination with Talazoparib in Patients with Triple-Negative Breast Cancer | philippe.aftimos@hubruxelles.be | 2 | 2 | |
22611 | *HER2+ invasive carcinoma of the breast *progressive disease with at least 2 non-bone 'target' metastatic lesions *biopsy of a metastatic site before inclusion |
Patrick Flamen | Breast | Institut Jules Bordet | ZEPHIR | Trial closed for recruitment | A phase II prospective imaging study evaluating the utility of pretreatment zirconium-89 labelled trastuzumab PET/CT and an early FDG-PET/CT response to identify patients with advanced HER-2 positive breast cancer unlikely to benefit from a novel anti-HER2 therapy : T-DM1 | patrick.flamen@hubruxelles.be | 2 | 2 | |
29237 | Michail Ignatiadis | Breast | GSK | ZEST | Trial closed for recruitment | A Randomized Phase 3 Double-Blinded Study Comparing Efficacy of Niraparib to Placebo in Participants with Either HER2-Negative BRCA-Mutated or Triple-Negative Breast Cancer with Molecular Disease Based on Presence of Circulating Tumor DNA after Definitive Therapy | michail.ignatiadis@hubruxelles.be | 3 | 3 | ||
22739 | *Single indeterminate renal mass <=7cm *scheduled nephrectomy within 90 days from planned Zr-TLX250 administration |
Carlos Artigas Guix | Kidney | Telix International Pty Ltd | ZIRCON | Trial closed | A confirmatory, prospective, open-label, multi-centre phase 3 study to evaluate diagnostic performance of 89Zirconium-labelled girentuximab(89Zr-TLX250) to non-invasively detect clear cell renal cell carcinoma (ccRCC) by positron emission tomography/CT (PET/CT) imaging in patients with indeterminate renal masses (ZIRCON Study) | carlos.artigas@hubruxelles.be | 3 | 3 |